FDA Issues Highest Risk Warning For Cheeseburger Recall
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A brand of cheeseburgers is being recalled due to undeclared allergens.
Sheehan Brothers Vending issued a voluntary recall for its Cheeseburgers, which were distributed across three states, due to undeclared sesame.
As a result, the Food and Drug Administration (FDA) has classified the recall as a Class I health risk, the most serious type of recall.
Why It Matters
According to the FDA, millions of people in the U.S. have food allergies or food sensitivities. Food sensitivities can range from mild reactions to potentially life-threatening symptoms. The agency recognizes nine major food allergens: milk, eggs, sesame, fish, tree nuts, crustacean shellfish, peanuts, wheat and soybeans.
File photo dated 09/07/14 of a generic stock photo of a pile of cheeseburgers and french fries.
File photo dated 09/07/14 of a generic stock photo of a pile of cheeseburgers and french fries.
Press Association/AP
What To Know
As well as the cheeseburgers, the company is also recalling its Spicy Chicken Sandwich, Italian Mini Subs, Pepperoni Pizza Sub, Chili Cheese Coney and BBQ Riblet with coleslaw due to undeclared sesame.
All the products have been issued a Class I health risk.
A Class I health risk, as defined by the FDA, is issued when there is a reasonable probability that the use of or exposure to a product will cause serious adverse health consequences or death. This designation signals that the product poses an immediate danger to public health and requires urgent attention from both consumers and health professionals.
The affected products were distributed in Indiana, Kentucky, and Ohio, specifically through Micro Markets and vending machines located throughout all of Ohio, northern Kentucky, and eastern Indiana. They were available for purchase between July 2 and July 8, 2025.
The issue was identified during a routine inspection conducted by the Ohio Department of Agriculture. While no illnesses have been reported in connection with the recalled items, individuals with a sesame allergy or severe sensitivity are at risk of experiencing a serious or potentially life-threatening allergic reaction if they consume the product.
All the affected products were wrapped in plastic.
What People Are Saying
The FDA, in an email to Newsweek in January: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service.
"The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall."
It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled."
What Happens Next
Consumers who have a sesame allergy or sensitivity are advised to dispose of the affected product immediately and contact Sheehan Brothers Vending to receive a replacement pack. Anyone experiencing signs or symptoms of a foodborne illness or allergic reaction should seek medical attention promptly.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
3 hours ago
- San Francisco Chronicle
UCSF doctor reinstated at FDA less than 2 weeks after resigning amid MAGA backlash
A divisive UCSF oncologist has reportedly been reinstated at the FDA less than two weeks after he resigned amid criticism from President Donald Trump's allies. Multiple media outlets on Saturday cited Health and Human Services Department officials confirming the reinstatement of Dr. Vinay Prasad, which was first reported by Endpoints News, a biotech-focused news organization. Spokespeople for HHS, which oversees the Food and Drug Administration, did not immediately respond to inquiries from the Chronicle about the news. Prasad resigned as the FDA's chief medical and scientific officer in late July after right-wing provocateur Laura Loomer and former Sen. Rick Santorum, R-Pa., accused him of being too liberal. He also drew backlash for criticizing the FDA's 2023 approval of a gene therapy for Duchenne muscular dystrophy, a degenerative muscle disease that affects boys, who often do not survive past their 20s. In his role at the FDA overseeing vaccines, Prasad announced in May that the agency would limit updated COVID-19 vaccine access to seniors and people with certain people with certain medical conditions. Previously, the FDA had recommended annual COVID shots for all Americans over 6 months old. On social media, Loomer criticized Prasad's reinstatement, calling him a 'longtime progressive Marxist.' 'In the coming weeks, I will be ramping up my exposes (sic) of officials within HHS and FDA so the American people can see more of the pay for play rot themselves and how rabid Trump haters continue to be hired in the Trump administration,' she wrote. 'Should be a good time.'
Yahoo
7 hours ago
- Yahoo
DeepHealth, a RadNet Subsidiary, Receives FDA Clearance for Remote Scanning Solution, TechLive™
TechLive™ is a vendor-agnostic integrated solution enabling remote scanning of MR, CT, PET/CT, and Ultrasound procedures Amidst radiology technologist shortages, remote scanning in a command center configuration enables the workforce to scan at multiple locations simultaneously with a high level of expertise RadNet has connected more than 300 MR, CT, PET/CT, and Ultrasound systems with TechLive™, delivering operational efficiency and increased access to advanced procedures LOS ANGELES and SOMERVILLE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and global leader in AI-powered health informatics, announced today that it has received FDA 510(k) clearance for TechLive™ - a remote scanning solution enabling centralized operation and supervision of MR, CT, PET/CT, and Ultrasound procedures. Amidst tech labor shortages and inflationary wage pressure, TechLive™ empowers technologists to scan for multiple locations, enables improved operational efficiency, extends center operating hours, and enhances access to complex procedures. More than 300 of RadNet's MR, CT, PET/CT, and Ultrasound systems are now connected with DeepHealth's TechLive™ solution, resulting in increased patient throughput and improved quality through remotely matching expert staff with complex modalities in real-time. Over the past decade, radiology workloads have steadily increased, while the number of qualified technologists have not grown proportionally. In a pilot deployment at 64 locations inside of RadNet's New York area facilities, TechLive™ significantly contributed to a 42% decrease in MRI room closure hours during the second quarter of 2025 as compared with the same period in 2024, allowing more patients to receive timely scans. Additionally, as a result of the remote expert involvement during the same pilot deployment, TechLive™ contributed to an increase in complex procedures. Furthermore, in extending remote scanning capabilities to Ultrasound, TechLive™ is enabling experienced senior sonographers and physicians to remotely guide technologists on-site through complex cases in a modality that is heavily dependent upon real-time, operator expertise. "TechLive™ represents a paradigm shift in how we approach imaging operations," said Sham Sokka, PhD, Chief Operating and Technology Officer at DeepHealth. "By enabling real-time remote expertise, we are not only addressing today's staffing challenges, we are creating a foundation for more efficient, financially sustainable, and high-quality patient care across the broadest set of imaging modalities. This FDA clearance validates DeepHealth's vision of a connected imaging ecosystem that scales human expertise beyond physical boundaries." About DeepHealthDeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (e.g., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth, Kheiron, and iCAD breast AI, Quantib prostate and brain AI, and See-Mode thyroid and breast AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. About RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 401 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit DeepHealth ContactAndra AxenteDirector of Communications+ RadNet, Inc. ContactMark StolperExecutive Vice President and Chief Financial Officer310-445-2800 Forward-Looking Statements This communication contains certain 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'outlook,' 'plan,' 'potential,' 'possible,' 'predict,' 'project,' 'seek, 'should,' 'target,' 'will' or 'would,' the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the streamlining of delivery and deployment across healthcare facilities, and TechLive creating a foundation for more efficient, financially sustainable and high-quality patient care across the broadest set of imaging modalities, and are qualified by the inherent risks and uncertainties surrounding future expectations generally, all of which are subject to change. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet's control. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations and assumptions regarding the future of RadNet's business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet's control. RadNet's actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet nor its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet's business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet's filings with the Securities and Exchange Commission (the 'SEC'), including the risk factors discussed in RadNet's most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC. Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.
Newsweek
8 hours ago
- Newsweek
Fifth Person in Florida Dies of Flesh-Eating Bacteria: What to Know
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A 78-year-old man is the fifth person in Florida this year to die from a Vibrio vulnificus infection, a bacterium referred to as "flesh-eating" because it can destroy skin and muscle tissue. Newsweek has reached out to Florida's Department of Health via email for comment on Saturday. Why It Matters While Vibrio vulnificus infections are rare, Florida saw a surge last year, with the state's Department of Health reporting 82 cases and 19 deaths, largely due to the impacts of Hurricane Helene. This year, 16 cases have been reported, with the latest death marking the fifth. CBS News reported 13 confirmed cases, and 8 deaths, citing state health agency officials. The bacteria typically grows in warm seawater and is part of a group of vibrios known as "halophilic" because they require salt, according to the Florida Department of Health. The bacteria is found in higher numbers when water temperatures are warmer, typically from May through October, according to the U.S. Centers for Disease Control and Prevention (CDC). What To Know The man was vacationing with his family on St. George Island, off Florida's Panhandle, when he reportedly contracted the bacteria through a cut on his leg, News Channel 8 reported. He developed a fever the next day. He then reportedly underwent five surgeries and two amputations, but ultimately, died on August 4. The Florida Department of Health warns against entering the water with fresh cuts or scrapes and advises immunocompromised individuals to wear protective footwear to avoid injuries from rocks and shells on the beach. People can also contract the bacteria by eating raw or undercooked shellfish, with the health department confirming that a death in July was caused by an infection after the person ate raw oysters. Cases are popping up along the Gulf, with the Louisiana Department of Health, in a July 30 press release, noting a recent uptick in cases. "To date this year, 17 cases of Vibrio vulnificus have been reported among Louisiana residents. All of these patients were hospitalized, and four of these illnesses resulted in death," the press release stated. The statement noted that the case count is much higher than in recent years, stating, "During the same time period over the previous 10 years, an average of seven Vibrio vulnificus cases and one death were reported each year." Inset: Grouping of Vibrio vulnificus bacteria revealed in the 13184x magnified scanning electron microscopic (SEM) image, 2005. A boat chugs along the Gulf as the sun sets over the horizon on March 19, 2020, in... Inset: Grouping of Vibrio vulnificus bacteria revealed in the 13184x magnified scanning electron microscopic (SEM) image, 2005. A boat chugs along the Gulf as the sun sets over the horizon on March 19, 2020, in the St. George Island section of Eastpoint, Florida. More Centers for Disease Control CDC /James Gathany/ Smith Collection/Gado/Getty Images/AP Photo/Julio Cortez What People Are Saying Public health physician and pulmonologist Dr. Vin Gupta told NBC News earlier this week: "[Vibrio vulnificus can] cause stomach upset, one very self-limited manifestation. The other that is vastly more serious is a wound infection which shows a hallmark skin rash that can really progress into a very severe infection. The third is a blood stream infection, which is what we are trying to avoid that can be life threatening, that's where early detection, early treatment is really critical." Aileen Marty, professor of Infectious Diseases, Florida International University, previously told Newsweek: "Cases have been rising as summers have grown warmer. The reason is that V. vulnificus is naturally found in warm, brackish coastal waters, especially in the Gulf Coast states (e.g., Florida, Texas, Louisiana, Alabama, Mississippi)." What Happens Next? Health officials advise against entering warm, salt or brackish water with open cuts or scrapes, or eating raw oysters and shellfish, and urge individuals who develop symptoms after exposure to seek medical attention immediately.
